NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors
about
Therapeutic Lymphoid Organogenesis in the Tumor MicroenvironmentCurrent perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptorsHVEM signalling promotes colitisCyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.Axl acts as a tumor suppressor by regulating LIGHT expression in T lymphoma.T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signalingCleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cellsThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunityTumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapyAdenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse modelsDepot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissueTolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.The presence of high level soluble herpes virus entry mediator in sera of gastric cancer patients.Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.FADD cleavage by NK cell granzyme M enhances its self-association to facilitate procaspase-8 recruitment for auto-processing leading to caspase cascadeGranzyme K inhibits replication of influenza virus through cleaving the nuclear transport complex importin α1/β dimer of infected host cells.Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growthHerpes virus entry mediator licenses Listeria infection induced immunopathology through control of type I interferon.Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulationImmunoregulation by tumor necrosis factor superfamily member LIGHTRecruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells.Roadmap to a better therapeutic tumor vaccine.A crucial role for HVEM and BTLA in preventing intestinal inflammationFoxO1-mediated autophagy is required for NK cell development and innate immunity.Lymphotoxin network pathways shape the tumor microenvironmentFrom cancer immunosurveillance to cancer immunotherapy.Targeting lymphocyte activation through the lymphotoxin and LIGHT pathwaysExpression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells.Targeting tumors with LIGHT to generate metastasis-clearing immunityLIGHT/IFN-γ triggers β cells apoptosis via NF-κB/Bcl2-dependent mitochondrial pathway.Expression of leukotriene B₄ receptor-1 on CD8⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity.Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partnersCostimulatory and coinhibitory receptors in anti-tumor immunityHVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effectRole of the tumor necrosis factor family member LIGHT in the pathogenesis of atopic dermatitis.
P2860
Q26799123-AA7DE718-3C15-43BE-A8BA-3C81423CD4EFQ27009135-C55F1CB5-1518-4349-B957-DDC5EF22C7B5Q28477792-5ADFCA4E-87BF-490D-BF45-DE36146EA2D0Q33502208-77C8A31A-C4BE-4B20-855E-C883755868B1Q33591281-32DF70CE-9132-45B6-87A8-41F88A66C32BQ33792958-55399B12-3284-43C8-A941-F873B4C1CC88Q33897748-D6E6AB34-5894-49FD-956F-30CA41F30515Q34073138-1FA537FB-1EDF-427E-B345-1900E9574C9FQ34137777-D4C6D402-7873-4B61-9F3B-99F43BA6787CQ34988018-2B2C3DE3-456A-411F-AB9B-E4C1FF037CD9Q35147250-442E8493-6138-4651-8CF5-D77321023D3DQ35610755-A1FA9144-0969-4EA5-8658-D7A722F3F823Q35812556-4FA46D02-8644-490A-9263-D0073036E570Q35839060-C7BEDC6B-7AF6-4082-9BB9-5CEB70260A7DQ35840521-DF8E882A-2340-409F-B956-D4236AEAE553Q35876302-210A2426-2A3B-4DF9-8FF8-1EBD26171FCAQ35902972-EA7C808A-9740-41A1-8711-59695557A18DQ35921725-94FAD75F-C3A6-4083-9FAE-01784BC54EC0Q35922058-A3FDE348-52D1-4195-A3EE-A09461E59867Q35933820-AD741806-F50C-44D5-BB12-69E80C402787Q36053977-177D1BB8-C48B-4C02-BC0A-60AA60B5572FQ36253506-1868239C-4C69-4C35-A007-B4A08EC1802DQ36603122-9593C8E2-2CC2-44EF-A866-E6900E70239EQ36684496-7ABB0DDC-A466-4ECF-B346-E6FACF0F960CQ36699814-C4E6575F-F9A8-4DAF-BF76-AE663FBE478EQ36765199-B5C2D59C-61CE-4DE2-AF9D-49022D2632F4Q36823937-F339D54C-9E4E-4F9B-91D2-71D6DA0DA7A1Q36990588-6F0F1A78-E8DB-4AFD-B43B-79AE6E84D8CDQ37036159-E26D6A94-C4FA-437A-9A3D-ED4D27006DB1Q37102329-5D8AD4FD-5559-4ED8-9EEC-4B6C6D6FE6F1Q37138965-4FF49A6E-8D9B-494B-9037-74EB19843F7FQ37175025-F8A55911-C208-4FE2-BE6F-0B94B80304CDQ37251618-DA66A4BC-B6C7-43AF-9407-DCE623E9A122Q37274068-58CC2C08-C9FD-463E-8873-39C8E79A5677Q37398839-01377B56-07B0-4070-91B7-24723CA41F11Q37474920-B939BF61-8F18-4F4E-B946-71962E8B2DD2Q37652960-E8EE7958-28F6-4B31-A8ED-E308785E9A67Q37684668-19EF5941-8FF0-47FC-91E3-9AD4D5C0D797Q37729679-B6102017-F01E-472C-A9AD-02A4E04921EFQ38999280-E78FE14D-8EAA-446D-80EA-CF24D70ED30C
P2860
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
NK-cell activation by LIGHT tr ...... y to reject established tumors
@ast
NK-cell activation by LIGHT tr ...... y to reject established tumors
@en
type
label
NK-cell activation by LIGHT tr ...... y to reject established tumors
@ast
NK-cell activation by LIGHT tr ...... y to reject established tumors
@en
prefLabel
NK-cell activation by LIGHT tr ...... y to reject established tumors
@ast
NK-cell activation by LIGHT tr ...... y to reject established tumors
@en
P2093
P2860
P1433
P1476
NK-cell activation by LIGHT tr ...... y to reject established tumors
@en
P2093
May Lynne Fu
Wenhua Liu
Yang-Xin Fu
Yonglian Sun
Yugang Wang
P2860
P304
P356
10.1182/BLOOD-2005-08-3485
P407
P577
2005-10-13T00:00:00Z